@article{MTMT:34797501,
	title = {Monogénesen öröklődő és szerzett autoinflammatoricus betegségek},
	url = {https://m2.mtmt.hu/api/publication/34797501},
	author = {Szekanecz, Zoltán and Szamosi, Szilvia and Benkő, Szilvia and Szűcs, Gabriella},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {165},
	unique-id = {34797501},
	issn = {0030-6002},
	year = {2024},
	eissn = {1788-6120},
	pages = {683-697}
}

@article{MTMT:34745209,
	title = {Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology},
	url = {https://m2.mtmt.hu/api/publication/34745209},
	author = {Simon, Diána and Kacsándi, Dorottya and Karancsiné Pusztai, Anita and Soós, Boglárka and Végh, Edit and Kerekes, György and Czókolyová, Monika and Szamosi, Szilvia and Szűcs, Gabriella and Prohászka, Zoltán and Németh, Péter and Berki, Tímea and Szekanecz, Zoltán},
	doi = {10.3390/ijms25063429},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {25},
	unique-id = {34745209},
	issn = {1661-6596},
	abstract = {Cardiovascular (CV) morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Natural autoantibodies (nAAb) are involved in innate immunity, as well as autoimmunity, inflammation, and atherosclerosis. There have not been any studies assessing the effects of biologics on nAAbs in RA and AS, also in relation to vascular pathophysiology. Fifty-three anti-TNF-treated RA and AS patients were included in a 12-month follow-up study. Anti-citrate synthase (CS) and anti-topoisomerase I fragment 4 (TOPO-F4) IgM and IgG levels were determined by ELISA. Ultrasonography was performed to assess brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV). Other variables were also evaluated at baseline and 6 and 12 months after treatment initiation. Anti-TNF therapy improved FMD in RA and PWV in AS and stabilized ccIMT. TNF inhibition increased anti-CS IgM and IgG, and possibly also anti-TOPO-F4 IgG levels. Various correlation analyses revealed that nAAbs might be independently involved in autoimmunity as well as changes in inflammation and vascular pathology over time in biologic-treated patients (p < 0.05). We also found associations between anti-TOPO-F4 IgG and anti-Hsp60 IgG (p < 0.05). Baseline nAAb levels or nAAb level changes might determine changes in CRP, disease activity, FMD, PWV, and ccIMT over time (p < 0.05). The interplay between arthritis and inflammatory atherosclerosis, as well as the effects of anti-TNF biologics on these pathologies, might independently involve nAAbs.},
	year = {2024},
	eissn = {1422-0067},
	orcid-numbers = {Prohászka, Zoltán/0000-0003-1761-7982; Berki, Tímea/0000-0002-0134-8127}
}

@article{MTMT:34775337,
	title = {AB0237 EFFECTS OF ONE-YEAR TOFACITINIB THERAPY ON ANGIOGENIC BIOMARKERS IN RHEUMATOID ARTHRITIS},
	url = {https://m2.mtmt.hu/api/publication/34775337},
	author = {Kerekes, György and Bodoki, Levente and Hamar, Attila and Karancsiné Pusztai, Anita and Tajti, Gábor and Katkó, Mónika and Végh, Edit and Pethő, Zsófia and Bodnár, Nóra and Horváth, Ágnes and Soós, B. and Szamosi, Szilvia and Hascsi, Z. and Harangi, Mariann and Panyi, György and Szűcs, Gabriella and Szekanecz, Zoltán},
	doi = {10.1136/annrheumdis-2023-eular.2331},
	journal-iso = {ANN RHEUM DIS},
	journal = {ANNALS OF THE RHEUMATIC DISEASES},
	volume = {82},
	unique-id = {34775337},
	issn = {0003-4967},
	year = {2023},
	eissn = {1468-2060},
	pages = {1303-1303},
	orcid-numbers = {Panyi, György/0000-0001-6227-3301}
}

@article{MTMT:34391690,
	title = {Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper},
	url = {https://m2.mtmt.hu/api/publication/34391690},
	author = {Spiera, Robert F. and Unizony, Sebastian and Warrington, Kenneth J. and Sloane, Jennifer and Giannelou, Angeliki and Nivens, Michael C. and Akinlade, Bolanle and Wong, Wanling and Bhore, Rafia and Lin, Yong and Buttgereit, Frank and Devauchelle-Pensec, Valerie and Rubbert-Roth, Andrea and Yancopoulos, George D. and Marrache, Frederic and Patel, Naimish and Dasgupta, Bhaskar},
	doi = {10.1056/NEJMoa2303452},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {389},
	unique-id = {34391690},
	issn = {0028-4793},
	year = {2023},
	eissn = {1533-4406},
	pages = {1263-1272},
	orcid-numbers = {Spiera, Robert F./0000-0003-2911-6800; Warrington, Kenneth J./0000-0001-7708-2487; Rubbert-Roth, Andrea/0000-0002-9016-2833}
}

@article{MTMT:34250233,
	title = {Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals},
	url = {https://m2.mtmt.hu/api/publication/34250233},
	author = {Szekanecz, Zoltán and Vokó, Zoltán and Surján, Orsolya and Rákóczi, Éva and Szamosi, Szilvia and Szűcs, Gabriella and Szekanecz, Éva and Müller, Cecília and Kiss, Zoltán},
	doi = {10.3389/fimmu.2023.1247129},
	journal-iso = {FRONT IMMUNOL},
	journal = {FRONTIERS IN IMMUNOLOGY},
	volume = {14},
	unique-id = {34250233},
	issn = {1664-3224},
	abstract = {Introduction
		In Hungary, the HUN-VE 3 study determined the comparative effectiveness of various primary and booster vaccination strategies during the Delta COVID-19 wave. That study included more than 8 million 18-100-year-old individuals from the beginning of the pandemic. Immunocompromised (IC) individuals have increased risk for COVID-19 and disease course might be more severe in them. In this study, we wished to estimate the risk of SARS-CoV-2 infection and COVID-19 related death in IC individuals compared to healthy ones and the effectiveness of the BNT162b2 vaccine by reassessing HUN-VE 3 data.
		Patients and methods
		Among the 8,087,988 individuals undergoing follow-up from the onset of the pandemic in the HUN-VE 3 cohort, we selected all the 263,116 patients with a diagnosis corresponding with IC and 6,128,518 controls from the second wave, before vaccinations started. The IC state was defined as two occurrences of corresponding ICD-10 codes in outpatient or inpatient claims data since 1 January, 2013. The control group included patients without chronic diseases. The data about vaccination, SARS-CoV-2 infection and COVID-19 related death were obtained from the National Public Health Center (NPHC) during the Delta wave. Cases of SARS-CoV-2 infection were reported on a daily basis using a centralized system via the National Public Health Center (NPHC).
		Results
		Out of the 263,116 IC patients 12,055 patients (4.58%) and out of the 6,128,518 healthy controls 202,163 (3.30%) acquired SARS-CoV-2 infection. Altogether 436 IC patients and 2141 healthy controls died in relation to COVID-19. The crude incidence rate ratio (IRR) of SARS-CoV-2 infection was 1.40 (95%CI: 1.37-1.42) comparing IC patients to healthy controls. The crude mortality rate ratio was 4.75 (95%CI: 4.28-5.27). With respect to SARS-CoV-2 infection, interestingly, the BNT162b2 vaccine was more effective in IC patients compared to controls. Primary vaccine effectiveness (VE) was higher in IC patients compared to controls and the booster restored VE after waning. VE regarding COVID-19 related death was less in IC patients compared to healthy individuals. Booster vaccination increased VE against COVID-19-related death in both IC patients and healthy controls.
		Conclusion
		There is increased risk of SARS-CoV-2 infection and COVID-19 related mortality in IC patient. Moreover, booster vaccination using BNT162b2 might restore impaired VE in these individuals.},
	year = {2023},
	eissn = {1664-3224},
	orcid-numbers = {Vokó, Zoltán/0000-0002-1004-1848; Kiss, Zoltán/0000-0002-4752-8529}
}

@article{MTMT:34215318,
	title = {Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis},
	url = {https://m2.mtmt.hu/api/publication/34215318},
	author = {Kerekes, György and Czókolyová, Monika and Hamar, Attila and Karancsiné Pusztai, Anita and Tajti, Gábor and Katkó, Mónika and Végh, Edit and Pethő, Zsófia and Bodnár, Nóra and Horváth, Ágnes and Soós, Boglárka and Szamosi, Szilvia and Hascsi, Zsolt and Harangi, Mariann and Hodosi, Katalin and Panyi, György and Seres, Tamás and Szűcs, Gabriella and Szekanecz, Zoltán},
	doi = {10.1093/rheumatology/kead502},
	journal-iso = {RHEUMATOLOGY},
	journal = {RHEUMATOLOGY (UNITED KINGDOM)},
	volume = {62},
	unique-id = {34215318},
	issn = {1462-0324},
	year = {2023},
	eissn = {1462-0332},
	pages = {SI304-SI312},
	orcid-numbers = {Panyi, György/0000-0001-6227-3301}
}

@article{MTMT:34185575,
	title = {Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis},
	url = {https://m2.mtmt.hu/api/publication/34185575},
	author = {Kacsándi, Dorottya and Fagyas, Miklós and Horváth, Ágnes and Végh, Edit and Pusztai, Anita and Czókolyová, Monika and Soós, Boglárka and Szabó, Attila Ádám and Hamar, Attila and Pethő, Zsófia and Bodnár, Nóra and Kerekes, György and Hodosi, Katalin and Szamosi, Szilvia and Szűcs, Gabriella and Papp, Zoltán and Szekanecz, Zoltán},
	doi = {10.3389/fmed.2023.1226760},
	journal-iso = {FRONT MED},
	journal = {FRONTIERS IN MEDICINE},
	volume = {10},
	unique-id = {34185575},
	year = {2023},
	eissn = {2296-858X}
}

@article{MTMT:34047238,
	title = {Gyulladásos bélbetegségekhez társuló spondylarthritis},
	url = {https://m2.mtmt.hu/api/publication/34047238},
	author = {Végh, Edit and Bodnár, Nóra and Szamosi, Szilvia and Szántó, Sándor Zoltán and Szűcs, Gabriella and Szekanecz, Zoltán},
	journal-iso = {MAGYAR REUMATOL},
	journal = {MAGYAR REUMATOLÓGIA},
	volume = {64},
	unique-id = {34047238},
	issn = {0139-4495},
	year = {2023},
	pages = {73-81},
	orcid-numbers = {Szántó, Sándor Zoltán/0000-0001-5030-6292}
}

@article{MTMT:33724256,
	title = {A szisztémás lupus erythematosus immunopatogenezise},
	url = {https://m2.mtmt.hu/api/publication/33724256},
	author = {Szamosi, Szilvia and Bodnár, Nóra and Bodoki, Levente and Gyetkó, Zsuzsanna and Horváth, Ágnes and Pethő, Zsófia and Tari, Dóra and Szekanecz, Zoltán and Szűcs, Gabriella},
	journal-iso = {IMMUNOLÓGIAI SZEMLE},
	journal = {IMMUNOLÓGIAI SZEMLE},
	volume = {15},
	unique-id = {33724256},
	issn = {2061-0203},
	year = {2023},
	pages = {34-46}
}

@article{MTMT:33457576,
	title = {Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach},
	url = {https://m2.mtmt.hu/api/publication/33457576},
	author = {Soos, Boglarka and Hamar, Attila and Karancsiné Pusztai, Anita and Czókolyová, Monika and Végh, Edit and Szamosi, Szilvia and Pethő, Zsófia and Gulyás, Katalin and Kerekes, György and Szántó, Sándor Zoltán and Szűcs, Gabriella and Christians, Uwe and Klawitter, Jelena and Seres, Tamas and Szekanecz, Zoltán},
	doi = {10.3389/fmed.2022.1011734},
	journal-iso = {FRONT MED},
	journal = {FRONTIERS IN MEDICINE},
	volume = {9},
	unique-id = {33457576},
	abstract = {IntroductionRheumatoid arthritis (RA) has been associated with changes in lipid, arginine and NO metabolism with increased cardiovascular (CV) risk. The aim of this study is to evaluate the effect of tofacitinib, a Janus kinase (JAK) inhibitor, on arginine and methionine metabolism in correlation with inflammation, functional and pathological vascular changes during one-year treatment of patients with RA. Materials and methodsThirty RA patients with active disease were treated with either 5 mg bid or 10 mg bid tofacitinib for 12 months. We determined DAS28, CRP, IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) levels. We assessed brachial artery flow-mediated vasodilation (FMD), carotid intima-media thickness (IMT) and pulse-wave velocity (PWV) by ultrasound at baseline and after 6 and 12 months. We also determined plasma L-arginine, L-citrulline, L-ornithine, inducible nitric oxide synthase (iNOS), asymmetric (ADMA) and symmetric dimethylarginine (SDMA), L-N-monomethyl-arginine (L-NMMA), cysteine, homocysteine, and methionine levels at these time points. ResultsTwenty-six patients (13 on each arm) completed the study. CRP, ESR and DAS28 decreased significantly during one-year treatment with tofacitinib. Arginine and ADMA showed a negative univariate correlation with CRP but not with FMD, PWV or IMT. Tofacitinib at 10 mg bid significantly increased L-arginine, L-ornithine, iNOS and methionine levels after 12 months. ADMA and SDMA levels did not change in our study. Methionine showed negative correlation with FMD at baseline and positive correlation with PWV after 12 months. No change was observed in FMD and PWV but a significant increase was measured in IMT at 6 and 12 months. Multivariate analysis indicated variable correlations of L-arginine, L-citrulline, ADMA, L-NMMA, homocysteine and methionine with DAS28, CRP, ESR and RF but not with anti-CCP after one-year treatment. With respect to vascular pathophysiology, only PWV and methionine correlated with each other. ConclusionOne-year tofacitinib treatment suppressed systemic inflammation and improved functional status in RA. FMD, PWV have not been affected by one-year tofacitinib treatment., while IMT increased further despite treatment. Increased arginine and methionine might contribute to the anti-inflammatory effects of tofacitinib. Increased arginine availability with no changing ADMA may protect FMD and PWV from deterioration. The increase of IMT in the anti-inflammatory environment cannot be explained by arginine or methionine metabolism in this study.},
	keywords = {ATHEROSCLEROSIS; arginine; rheumatoid arthritis; metabolomics; METHIONINE; Tofacitinib},
	year = {2022},
	eissn = {2296-858X},
	orcid-numbers = {Szántó, Sándor Zoltán/0000-0001-5030-6292}
}